Altimmune to Host Virtual R&D Day on March 13, 2025

Rhea-AI Summary

Altimmune (Nasdaq: ALT) has announced a virtual R&D Day scheduled for March 13, 2025 at 12:00 pm Eastern Time. The event will showcase presentations from Key Opinion Leaders (KOLs) focusing on multiple therapeutic areas for pemvidutide:

• Obesity treatment applications
• MASH (Metabolic Dysfunction-Associated Steatohepatitis)
• Two additional newly FDA-cleared indications

The R&D Day will cover the scientific basis for pemvidutide across these indications, review existing clinical data, and outline development strategies. A significant highlight will be discussing the upcoming topline data from the IMPACT Phase 2b trial in MASH, expected in Q2 2025. The event will be accessible through https://investorday.altimmune.com and the company's website Events section.

News Market Reaction

-2.27%

1 alert

-2.27% News Effect

On the day this news was published, ALT declined 2.27%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA

GAITHERSBURG, M.D., March 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time.

The event will include presentations from renowned Key Opinion Leaders (KOLs) in obesity, MASH and each of the two additional indications, covering the scientific rationale for pemvidutide in each indication, clinical data generated to-date and plans for the continued development of pemvidutide, including the upcoming topline data readout from IMPACT, the Company’s Phase 2b trial in MASH, which is expected in the second quarter of 2025.

The event will be available at https://investorday.altimmune.com and via the Events section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH and other indications. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
danielle.cantey@inizioevoke.com

This press release was published by a CLEAR® Verified individual.

FAQ

When is Altimmune's (ALT) R&D Day and how can investors access it?

Altimmune's R&D Day is on March 13, 2025, at 12:00 pm ET. Investors can access it at https://investorday.altimmune.com or through the Events section of Altimmune's website.

What are the main indications being discussed for pemvidutide at ALT's R&D Day?

The R&D Day will cover pemvidutide's applications in obesity, MASH, and two additional indications that recently received FDA IND clearance.

When will Altimmune (ALT) release topline data from the IMPACT trial for MASH?

Altimmune expects to release topline data from the Phase 2b IMPACT trial in MASH during the second quarter of 2025.

What key topics will be covered during Altimmune's 2025 R&D Day presentation?

The event will cover scientific rationale for pemvidutide, current clinical data, and development plans across multiple indications, featuring presentations from Key Opinion Leaders.